IL173294A - A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it - Google Patents

A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it

Info

Publication number
IL173294A
IL173294A IL173294A IL17329406A IL173294A IL 173294 A IL173294 A IL 173294A IL 173294 A IL173294 A IL 173294A IL 17329406 A IL17329406 A IL 17329406A IL 173294 A IL173294 A IL 173294A
Authority
IL
Israel
Prior art keywords
ylmethyl
piperazinyl
biphenyl
preparation
pharmaceutical compositions
Prior art date
Application number
IL173294A
Other versions
IL173294A0 (en
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/051816 external-priority patent/WO2005016898A2/en
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of IL173294A0 publication Critical patent/IL173294A0/en
Publication of IL173294A publication Critical patent/IL173294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL173294A 2003-08-18 2006-01-23 A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it IL173294A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49570803P 2003-08-18 2003-08-18
EP03102573 2003-08-18
PCT/EP2004/051816 WO2005016898A2 (en) 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesilate

Publications (2)

Publication Number Publication Date
IL173294A0 IL173294A0 (en) 2006-06-11
IL173294A true IL173294A (en) 2010-12-30

Family

ID=34196156

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173294A IL173294A (en) 2003-08-18 2006-01-23 A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it

Country Status (4)

Country Link
KR (1) KR20060073939A (en)
HK (1) HK1091206A1 (en)
HR (1) HRP20110303T1 (en)
IL (1) IL173294A (en)

Also Published As

Publication number Publication date
IL173294A0 (en) 2006-06-11
HRP20110303T1 (en) 2011-05-31
KR20060073939A (en) 2006-06-29
HK1091206A1 (en) 2007-01-12

Similar Documents

Publication Publication Date Title
PL396568A1 (en) Crystalline O-desmethyl-venlafaxine succinate, the pharmaceutical composition, pharmaceutical dosage form, oral dosage form, application and process for the preparation of crystalline O-desmethyl-venlafaxine succinate
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
IL219818A0 (en) Pharmaceutically acceptable salts of quinolinone compounds improved pharmaceutical properties
IL163831A (en) Derivatives of aminoindazoles, pharmaceutical compositions comprising them, process for their preparation and use thereof
HUP0402161A3 (en) Nicotin-or isonicotin benzothiazole derivatives, process for their preparation and pharmaceutical compositions containing them
CA2252895A1 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
IL185537A0 (en) 7 - (2 - (4 - (3 - trifluoromethyl - phenyl) - 1, 2, 3, 6 - tetrahydro - pyrid - 1 - yl) ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
AU2003221078A1 (en) Therapeutic composition for bone infectious disease
IS8279A (en) Stable crystalline form of bifeprunox mesilate (7- [4 - ([1,1'-biphenyl] -3-ylmethyl) -1-piperazinyl] -2 (3H) -benzoxazolone monomethanesulfonate
IL161348A (en) Substituted 4- phenyl-4-[1h - imidazol-2-yl] piperidine derivatives and their use for the preparation of pharmaceutical compositions
IL172005A0 (en) Crystalline ziprasidone hci and process for preparation thereof
IL173294A (en) A crystalline polymorph of (7 - [4 - ([1,1'- biphenyl] - 3 - ylmethyl) - 1 - piperazinyl] - 2 (3h) - benzoxazolone monomethanesulfonate, process for its preparation and pharmaceutical compositions comprising it
IL172629A0 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
HUP0200865A2 (en) Thiazolidinedione derivative and its use as antidiabetic, process for its preparation and pharmaceutical compositions containing it
AU2003260813A1 (en) Improved process for preparation of thiazolidinedione derivatives
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
HUP0200785A2 (en) Thiazolidinedione derivative and its use as antidiabetic, process for its preparation and pharmaceutical composition containing it
HUP0600347A3 (en) Process for the preparation of {2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one (ziprasidon) and the intermediate
AU2003263480A8 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability
IL162101A (en) Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments
EP1556364A4 (en) Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same
AU2003277298A8 (en) Pharmaceutical compositions for treatment of parkinson's disease
FR2843955B1 (en) PROCESS FOR THE PREPARATION OF INORGANIC OXIDE POWDERS, CRYSTALLINE COMPOUNDS AND THE USE THEREOF
AU2003904835A0 (en) Crystallisation of Crystalline Titanium Oxides

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees